Pα+ Psychedelic Bulletin #160: Mutual Recognition for MDMA-AT in the UK? Beckley Shares Cut of 5-MeO-DMT Data; and more – Psychedelic Alpha

Featured content in this Issue:

  • A Look at Potential Mutual Recognition of FDA Approval for Psychedelics Via the UK MHRA’s International Recognition Procedure
  • Beckley Psytech Shares Topline Data from Phase 2a Study of 5-MeO-DMT for TRD
  • Other News from Compass Pathways, Numinus, the UN Commission on Narcotic Drugs, and more.

Companies, organisations and drug candidates mentioned in this Bulletin: Lykos Therapeutics, MDMA-assisted therapy; Compass Pathways; COMP360; MHRA; Beckley Psytech; BPL-003; GH Research; GH001; Numinus; PharmAla Biotech; NIDA; MindBio.

This is the first issue of our Psychedelic Bulletin that’s exclusively for Pα+ subscribers. Head to our Join page to learn more, or sign in to your account.

Sign-in button

Join Button

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.

Subscribe

* indicates required